



**Our laboratory has received this rating in all 29 editions**

## **ESTEVE'S R&D, AGAIN RATED 'EXCELLENT' BY PROFARMA PLAN**

**Barcelona, 7 March 2016.-** The Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) of the Ministry of Industry, Energy and Tourism has one more year rated ESTEVE's R&D activities as 'excellent'. This is the 29<sup>th</sup> consecutive time that our laboratory receives this seal of quality, ever since the launch of Profarma in 1986.

ESTEVE is classified in Group A of the Proforma Plan (2013-2016), which includes pharmaceutical companies with significant research activities that have their own production center or basic or preclinical R&D.

Innovation and internationalization are two strategic axes at ESTEVE, a company that invests 63 million Euros a year in research and has a workforce of 2,279 professionals, 10% of which devoted exclusively to R&D activities. This firm commitment and effort have again resulted in the annual renovation of the maximum rating granted by Profarma, an official seal of quality that fosters R&D in the pharmaceutical sector.

### **About ESTEVE**

ESTEVE ([www.esteve.com](http://www.esteve.com)) is a leading chemical-pharmaceutical group in Spain with a strong international presence. Founded in 1929 and presided over by Joan Esteve, it currently employs nearly 2,300 people, has a presence in Europe, USA, Mexico and China, and had a sales revenue of 870 million Euros in 2015. Firmly committed to excellence, the Company uses its best efforts to promote health and improve people's quality of life. Research being ESTEVE's hallmark, a portfolio of highly innovating projects ultimately aims to provide responses to unmet medical needs. Because ESTEVE is a socially responsible Company, it ensures that all projects entered by it align with its CSR vision. You may follow ESTEVE at Twitter's link: @ESTEVE\_news

### **About Profarma**

The Profarma Plan is a joint initiative of the Ministry of Industry, Energy and Tourism, of the Ministry of Economy and Competitiveness, and of the Ministry of Health, Social Services and Equality. The objective of this plan is to promote the performance of R&D&I activities in the pharmaceutical sector and to foster competitiveness. Company ratings are based on industrial, economic and R&D parameters.

### **For more information, please contact:**

M<sup>a</sup> José Egea, Atrivia, Tel. 93 419 06 30, [miegea@atrevia.com](mailto:miegea@atrevia.com)  
Olga Cajal, ESTEVE, Tel. 93 446 62 60, [ocajal@esteve.es](mailto:ocajal@esteve.es)